244 related articles for article (PubMed ID: 27034938)
1. Thyroid Remnant Estimation by Diagnostic Dose (131)I Scintigraphy or (99m)TcO4(-) Scintigraphy after Thyroidectomy: A Comparison with Therapeutic Dose (131)I Imaging.
Liu G; Li N; Li X; Chen S; Du B; Li Y
Biomed Res Int; 2016; 2016():4763824. PubMed ID: 27034938
[TBL] [Abstract][Full Text] [Related]
2. RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system.
Zeuren R; Biagini A; Grewal RK; Randolph GW; Kamani D; Sabra MM; Shaha AR; Tuttle RM
Laryngoscope; 2015 Oct; 125(10):2417-24. PubMed ID: 25891354
[TBL] [Abstract][Full Text] [Related]
3. Technetium-99m-pertechnetate whole-body SPET/CT scan in thyroidectomized differentiated thyroid cancer patients is a useful imaging modality in detecting remnant thyroid tissue, nodal and distant metastases before
Lou K; Gu Y; Hu Y; Wang S; Shi H
Hell J Nucl Med; 2018; 21(2):121-124. PubMed ID: 30089313
[TBL] [Abstract][Full Text] [Related]
4.
Giovanella L; Paone G; Ruberto T; Ceriani L; Trimboli P
Endocrinol Metab (Seoul); 2019 Mar; 34(1):63-69. PubMed ID: 30784242
[TBL] [Abstract][Full Text] [Related]
5. The role of postoperative Tc-99m pertechnetate scintigraphy in estimation of remnant mass and prediction of successful ablation in patients with differentiated thyroid cancer.
Ozdemir D; Cuhaci FN; Ozdemir E; Aydin C; Ersoy R; Turkolmez S; Cakir B
Nucl Med Commun; 2016 Jun; 37(6):640-5. PubMed ID: 26895488
[TBL] [Abstract][Full Text] [Related]
6. Combined use of radioiodine therapy and radiofrequency ablation in treating postsurgical thyroid remnant of differentiated thyroid carcinoma.
Long B; Li L; Yao L; Chen S; Yi H; Ye X; Xu D; Wu P
J Cancer Res Ther; 2015 Nov; 11 Suppl():C244-7. PubMed ID: 26612446
[TBL] [Abstract][Full Text] [Related]
7. Thyroid remnant estimation by Tc-99m-sestamibi scanning predicts the effectiveness of rhTSH-stimulated I-131 ablation in patients with differentiated thyroid carcinoma.
Giovanella L; Suriano S; Castellani M; Ceriani L; Verburg FA
Clin Nucl Med; 2011 Sep; 36(9):781-5. PubMed ID: 21825849
[TBL] [Abstract][Full Text] [Related]
8. The correlation of post-operative radioiodine uptake and Tc-99m pertechnetate thyroid scintigraphy and the result of thyroid remnant ablation.
Thientunyakit T; Pusuwan P; Tuchinda P; Khiewvan B
J Med Assoc Thai; 2013 Sep; 96(9):1199-207. PubMed ID: 24163997
[TBL] [Abstract][Full Text] [Related]
9. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect.
Yap BK; Murby B
J Clin Endocrinol Metab; 2014 Jul; 99(7):2433-40. PubMed ID: 24762114
[TBL] [Abstract][Full Text] [Related]
10. Postsurgical thyroid remnant estimation by (⁹⁹m) Tc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
Giovanella L; Suriano S; Ricci R; Ceriani L; Anton Verburg F
Head Neck; 2011 Apr; 33(4):552-6. PubMed ID: 20824809
[TBL] [Abstract][Full Text] [Related]
11. Role of Tc-99m pertechnetate for remnant scintigraphy, post-thyroidectomy, and serum thyroglobulin and antithyroglobulin antibody levels in the patients with differentiated thyroid cancer.
Aydin F; Sipahi M; Budak ES; Oner AO; Demirelli S; Erkilic M; Gungor F
Ann Nucl Med; 2016 Jan; 30(1):60-7. PubMed ID: 26462671
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
13. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
14. Prediction of the success of thyroid remnant ablation using preablative 99mTc pertechnetate scintigraphy and postablative dual 131I scintigraphy.
Jung JS; Lee SM; Kim SJ; Choi J; Han SW
Nucl Med Commun; 2015 Jan; 36(1):38-44. PubMed ID: 25299469
[TBL] [Abstract][Full Text] [Related]
15. Enhanced scintigraphic visualization of thyroglossal duct remnant during hypothyroidism after total thyroidectomy: prevalence and clinical implication in patients with differentiated thyroid cancer.
Lee SW; Lee J; Lee HJ; Seo JH; Kang SM; Bae JH; Ahn BC
Thyroid; 2007 Apr; 17(4):341-6. PubMed ID: 17465864
[TBL] [Abstract][Full Text] [Related]
16. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
[TBL] [Abstract][Full Text] [Related]
17. Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer.
Campennì A; Violi MA; Ruggeri RM; Sindoni A; Moleti M; Vermiglio F; Baldari S
Nucl Med Commun; 2010 Apr; 31(4):274-9. PubMed ID: 20087239
[TBL] [Abstract][Full Text] [Related]
18. The relationship between the quantitative evaluation of thyroid bed uptake and the disappearance of accumulation in adjuvant radioactive iodine therapy for differentiated thyroid cancer.
Konishi K; Ishiba R; Ikenohira T; Asao T; Hirata M; Ohira K; Komatsu T; Sawada M; Tanahashi Y; Goshima S; Magata Y; Nakamura K
Ann Nucl Med; 2021 Feb; 35(2):159-166. PubMed ID: 33387279
[TBL] [Abstract][Full Text] [Related]
19. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of thyroglossal tract thyroid tissue on SPECT/CT following (131) I ablation therapy after total thyroidectomy for thyroid cancer.
Barber TW; Cherk MH; Topliss DJ; Serpell JW; Yap KS; Bailey M; Kalff V
Clin Endocrinol (Oxf); 2014 Aug; 81(2):266-70. PubMed ID: 24483626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
